Clinical trial · Observational
Health Care Utilisation Among Survivors of Childhood Acute Lymphoblastic Leukaemia
Health Care Utilisation Following Childhood Acute Lymphoblastic Leukaemia: A Matched Cohort Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Improved understanding of the long-time healthcare utilisation of childhood cancer survivors is relevant as it can be seen as a proxy for the population's morbidity. The investigators will conduct a historic population-based matched cohort study using Danish nationwide registry data. Eligible children are children 1.0-17.9 years diagnosed with Acute lymphoblastic leukaemia (ALL) in Denmark from 1994 till 2016. The primary outcome is yearly contact rates to primary healthcare.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | Acute Lymphoblastic Leukemia | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Diagnosis of and treatment for Acute lymphoblastic leukaemia in childhood | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Childhood ALL survivors
- description
- The cohort of childhood ALL survivors will be identified in the Danish part of the Nordic Society of Paediatric Haematology and Oncology (NOPHO) ALL-Register .
- interventionNames
- Other: Diagnosis of and treatment for Acute lymphoblastic leukaemia in childhood
- label
- Comparison cohort
- description
- A reference cohort (comparison cohort) of individuals will be sampled randomly from the source population matched by age and sex and without a history of childhood cancer in the calendar year where the case was diagnosed (density sampling). For each childhood ALL-patient we will choose ten comparison subjects.
Primary outcomes (1)
- measure
- The yearly contact rate to general practice for ALL survivors and controls
- timeFrame
- 1-20 years follow-up
- description
- Analysing longitudinal health care data with analysis of both first and recurrent events
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 1 Year
- Maximum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * B-precursor ALL and T-ALL enrolled in the NOPHO ALL-92, ALL-2000 and ALL-2008 trials. * Treated at one of the four Danish paediatric oncology departments * Age group 1.0-14.9 for the NOPHO ALL-92 and ALL-2000 trials. Age group 1.0-17.9 for the NOPHO ALL-2008 trial. * Completed maintenance therapy in the time period form 01.01.1997 till 31.12.2016 Exclusion Criteria: * Children with Down syndrome
References
Publications (1)
- DERIVEDJensen KS, Klug Albertsen B, Schroder H, Zalounina Falborg A, Schmiegelow K, Rosthoj S, Callesen MT, Vedsted P. Health care utilisation following childhood acute lymphoblastic leukaemia: a population-based matched cohort study. BMJ Open. 2021 Nov 22;11(11):e049847. doi: 10.1136/bmjopen-2021-049847. PMID 34810184